Advertisement

Table of contents

  1. Front Matter
    Pages I-VII
  2. M. J. McConnell, J. D. Licht
    Pages 31-48
  3. J. -S. Seeler, O. Bischof, K. Nacerddine, A. Dejean
    Pages 49-71
  4. C. Nervi, F. Fazi, A. Rosa, A. Fatica, I. Bozzoni
    Pages 73-84
  5. P. P. Scaglioni, P. P. Pandolfi
    Pages 85-100
  6. P. Fenaux, Z. Z. Wang, L. Degos
    Pages 101-128
  7. Z. Chen, W. -L. Zhao, Z. -X. Shen, J. -M. Li, S. -J. Chen, J. Zhu et al.
    Pages 129-144
  8. K. Petrie, N. Prodromou, A. Zelent
    Pages 157-203
  9. P. G. Maslak, J. G. Jurcic, D. A. Scheinberg
    Pages 205-219
  10. Back Matter
    Pages 271-276

About this book

Introduction

Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development  of targeted therapy.

Keywords

All-trans retinoic acid (ATRA) Chromosom Small ubiquitin-like modifier (SUMO) clinical trial genes genetics leukemia microRNA molecular genetics peptides protein proteins targeted therapy transcription translation

Editors and affiliations

  • Pier Paolo Pandolfi
    • 1
  • Peter K. Vogt
    • 2
  1. 1.Memorial Sloan-Kettering Cancer CenterSloan-Kettering-InstituteNew YorkUSA
  2. 2.The Scripps Research InstituteLa JollaUSA

Bibliographic information